Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec Enters Biology Collaboration with Probiodrug

Published: Thursday, November 29, 2012
Last Updated: Thursday, November 29, 2012
Bookmark and Share
Evotec will setup and validate assays to support the pre-clinical and clinical development of QC inhibitors in Alzheimer’s disease.

Evotec AG has announced that it has entered into a collaboration with Probiodrug AG, a privately owned biopharmaceutical company focused on the development of innovative drugs for the treatment of major age related diseases.

Under the terms of the agreement, Evotec will setup and validate assays to support the pre-clinical and clinical development of glutaminyl cyclase (QC) inhibitors for the treatment of Alzheimer’s disease.

Glutaminyl cyclase is a novel proprietary enzyme target discovered and validated by Probiodrug which plays a crucial role in the pathogenesis of Alzheimer’s disease (AD) as well as potentially other diseases.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: “We are pleased to enter this collaboration with Probiodrug to use our first class assay development capabilities to support the pre-clinical and clinical development of QC inhibitors in Alzheimer’s disease and other indications. This is a good example of how Evotec can support Biotech companies with their specific drug discovery needs.”

Hendrik Liebers, Chief Financial Officer of Probiodrug, added: “The collaboration will allow us to focus on the further pre-clinical and clinical development of our programmes in neurodegeneration/AD. Evotec, with its proven track record, is ideally suited to accompany this process by running existing and developing new biological assays.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec and Padlock Therapeutics Extend Collaboration
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration.
Friday, January 09, 2015
Evotec, Fraunhofer in Drug Discovery Collaboration
The exclusive, strategic collaboration will combine the relevant platforms of both organisations, focusing on several disease areas.
Tuesday, July 08, 2014
Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
The milestone relates to the transition of an oncology molecule into pre-clinical development.
Tuesday, December 10, 2013
Evotec Receives Pre-clinical Milestone Payment
Evotec AG announces that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec.
Friday, August 19, 2011
Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression
The proof-of-concept Phase II trial will study the safety and tolerability of EVT 101 while also exploring the efficacy of this intervention.
Thursday, July 01, 2010
Evotec Reports Progress in Product Development in Treatment-Resistant Depression in its Alliance with Roche
Company completion its first-in-man study with EVT 103 and receives a positive feedback from the FDA to initiate Phase II with EVT 101.
Thursday, March 11, 2010
Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical
Ono to access Evotec’s ion channel drug discovery platform and expertise and Evotec to receive research funding and milestone payments.
Monday, October 19, 2009
Evotec Starts Phase I with EVT 103, an NR2B-selective NMDA Receptor Antagonist
EVT 103 is currently planned to enter clinical development for treatment-resistant depression in collaboration with Roche.
Wednesday, September 09, 2009
Evotec Announces the Successful Completion of the First Phase I Study with EVT 401
The double-blind, placebo controlled study showed that the compound was safe and well tolerated without any serious adverse events.
Friday, July 10, 2009
Evotec Acquires Zebrafish Screening Operations of Summit Corporation
The acquisition against £ 0.5 million cash in 2009 expected to add approximately £ 1.5 million revenues in 2010.
Friday, May 08, 2009
Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302
Study fails to demonstrate any significant improvement in the quit rate compared with placebo.
Monday, April 20, 2009
Evotec Presents its Fragment Screening Technology at Two Key Conferences
Presentations will be given at Screening, MedChem and ADMET Europe and at the Molecular Medicine Tri-Conference.
Thursday, February 19, 2009
Evotec Reports Phase I Safety Data from Tyramine Interaction Study with EVT 302
The study was undertaken to determine potential safety advantages of EVT 302 versus non-selective MAO inhibitors and less selective MAO-B inhibitors.
Monday, November 03, 2008
Evotec Announces Phase I Initiation with P2X7 Antagonist
P2X7 receptor antagonism may provide a novel approach to the treatment of rheumatoid arthritis and other inflammatory conditions.
Friday, October 10, 2008
Evotec’s EVT 101 Well Tolerated in Four Week Higher Repeat Dose Safety Study
The study showed in both young and elderly subjects that EVT 101 was well tolerated up to the highest dose tested.
Friday, July 04, 2008
Scientific News
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Novel Technique for Kidney Research Developed
To better understand how the treatment leads to kidney damage, and possibly prevent it, a team of researchers at Yale School of Medicine developed a new 3D-imaging technique to peer deep into these vital organs.
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
A Better Way to Personalize Bladder Cancer Treatments
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.
Breath of Fresh Air for Asthmatics
Researchers hope to develop a platform that will allow a range of drugs to be delivered by inhalation.
Capturing Cell Growth in 3-D
Spinout’s microfluidics device better models how cancer and other cells interact in the body.
Elastic Patch Releases Drugs in a Stretch
Researchers from have developed a drug delivery technology that consists of an elastic patch that can be applied to the skin and will release drugs whenever the patch is stretched.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Liposomes: A Basis for Drugs of the Future
An international group of scientists have recently presented a review of liposomes, microscopic capsules widely used all over the world in the development of new drugs.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!